Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement - Salarius Pharmaceuticals (NASDAQ:SLRX)

Core Points - Salarius Pharmaceuticals has regained compliance with Nasdaq's Minimum Bid Price Requirement as of September 4, 2025 [1][2] - The company has until October 20, 2025, to comply with Nasdaq's Equity Standard Requirement [2] - Salarius will be under a Mandatory Panel Monitor for one year starting September 4, 2025, to ensure compliance [3] Merger Details - Salarius announced a definitive merger agreement with Decoy Therapeutics, a preclinical biopharmaceutical company, on January 13, 2025 [4] - The merger aims to create value through Decoy's peptide conjugate therapeutics pipeline, targeting unmet medical needs in respiratory infectious diseases and GI oncology [5] - The combined company will incorporate Salarius' SP-3164 into a peptide-based PROTACS drug candidate [5] Leadership and Development Plans - The new company will be led by Decoy's co-founders and Salarius' acting CEO and CFO [6] - Decoy plans to advance its lead asset, a pan-coronavirus antiviral, to an IND application with the FDA within the next 12 months [7] - Salarius' seclidemstat is being evaluated in a Phase 1/2 clinical study for hematologic cancers [8] About Decoy Therapeutics - Decoy Therapeutics focuses on designing and manufacturing peptide conjugate drug candidates using machine learning and AI [9] - The company has received funding from various sources, including institutional investors and government programs [9] About Salarius Pharmaceuticals - Salarius is a clinical-stage biopharmaceutical company with two drug candidates for cancer treatment [10] - The lead candidate, seclidemstat, is in a clinical study for myelodysplastic syndrome and chronic myelomonocytic leukemia [10]